Article Text

Download PDFPDF
Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh et al
  1. Alexis Mathian,
  2. Zahir Amoura
  1. Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
  1. Correspondence to Dr Alexis Mathian, Internal Medicine, University Hospital Pitié Salpêtrière, 75651 Paris, France; alexis.mathian{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Teh et al for their interest in our study reporting on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 in a case series of patients with systemic lupus erythematosus (SLE) under long-term treatment with hydroxychloroquine (HCQ).1 2 Teh et al report in detail the clinical course of COVID-19 in five patients with SLE in Malaysia. All patients were women, 50 years old on average, under long-term HCQ treatment, and the majority were suffering from comorbidities such as hypertension, obesity or diabetes. All patients presented with moderately severe to severe COVID-19; one patient died and another needed invasive ventilation. In this respect, the series of patients with SLE infected with SARS-CoV-2 described by Teh et al resemble other series previously reported by our group and others, encompassing a low number of patients, often hospitalised, with a majority of women in their 50s suffering from various comorbidities and an occasional severe or even lethal clinical evolution.1 3 However, these case series do …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors AM and ZA wrote the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles